Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Emilie R Elliot
Observed names:
E Elliot,
E. Elliot,
Elliot, Emilie,
Emilie Elliot,
Emilie R. Elliot
Institution:
ViiV Healthcare (Spain)
Observed institutions:
University of Liverpool,
ViiV Healthcare (Spain),
Chelsea and Westminster Hospital NHS Foundation Trust,
ViiV Healthcare (United Kingdom),
Chelsea and Westminster Hospital,
St Stephen’s AIDS Trust
show all 6
ORCID:
0000-0001-7736-9883
Observed ORCID:
0000-0001-7736-9883
OpenAlex ID:
A5011969265
Identifying undiagnosed HIV in men who have sex with men (MSM) by offering HIV home sampling via online gay social media: a service evaluation
2016
·
E Elliot
, M Rossi
, et al.
·
Sexually Transmitted Infections
·
75
Increased Dolutegravir Peak Concentrations in People Living With Human Immunodeficiency Virus Aged 60 and Over, and Analysis of Sleep Quality and Cognition
2018
·
Emilie R Elliot
, Xinzhu Wang
, et al.
·
Clinical Infectious Diseases
·
63
PDF
The development and application of a novel LC–MS/MS method for the measurement of Dolutegravir, Elvitegravir and Cobicistat in human plasma
2016
·
Sujan Dilly Penchala
, Sandra Fawcett
, et al.
·
Journal of Chromatography B
·
43
Iatrogenic Cushing’s syndrome due to drug interaction between glucocorticoids and the ritonavir or cobicistat containing HIV therapies
2016
·
Emilie R Elliot
, Aikaterini Theodoraki
, et al.
·
Clinical Medicine
·
41
PDF
Dolutegravir and elvitegravir plasma concentrations following cessation of drug intake
2015
·
Emilie Elliot
, Alieu Amara
, et al.
·
Journal of Antimicrobial Chemotherapy
·
40
How recent findings on the pharmacokinetics and pharmacodynamics of integrase inhibitors can inform clinical use
2016
·
Emilie Elliot
, Mimie Chirwa
, et al.
·
Current Opinion in Infectious Diseases
·
29
Cabotegravir + Rilpivirine Long-Acting: Overview of Injection Guidance, Injection Site Reactions, and Best Practices for Intramuscular Injection Administration
2024
·
Paula Teichner
, Nadine Chamay
, et al.
·
Open Forum Infectious Diseases
·
24
Genetic influence of ABCG2, UGT1A1 and NR1I2 on dolutegravir plasma pharmacokinetics
2019
·
Emilie R Elliot
, Megan Neary
, et al.
·
Journal of Antimicrobial Chemotherapy
·
23
Efficacy, Safety, and Pharmacokinetics by Body Mass Index Category in Phase 3/3b Long-Acting Cabotegravir Plus Rilpivirine Trials
2023
·
Emilie R Elliot
, Joseph W Polli
, et al.
·
The Journal of Infectious Diseases
·
20
PDF
Pharmacokinetics of dolutegravir with and without darunavir/cobicistat in healthy volunteers
2018
·
Emilie R Elliot
, Maddalena Cerrone
, et al.
·
Journal of Antimicrobial Chemotherapy
·
11
PDF
Practical dosing guidance for the management of clinician-administered injections of long-acting cabotegravir and rilpivirine
2023
·
Parul Patel
, Paula Teichner
, et al.
·
Therapeutic Advances in Infectious Disease
·
8
Once-daily atazanavir/cobicistat and darunavir/cobicistat exposure over 72 h post-dose in plasma, urine and saliva: contribution to drug pharmacokinetic knowledge
2017
·
Emilie R. Elliot
, Alieu Amara
, et al.
·
Journal of Antimicrobial Chemotherapy
·
8
PDF
O20 Home sampling through social network websites: can we reduce undiagnosed HIV?
2012
·
E Elliot
, A McCowan
, et al.
·
Sexually Transmitted Infections
·
6
PDF
Pharmacokinetics (PK) of ethinylestradiol/levonorgestrel co-administered with atazanavir/cobicistat
2019
·
Emilie R Elliot
, Elisa Bisdomini
, et al.
·
HIV Research & Clinical Practice
·
4
PDF
Long-Acting Cabotegravir Injections Are More Acceptable Than Long-Acting Lenacapavir Injections After One Dose: Results From the CLARITY Randomized Crossover Study
2026
·
Emilie R. Elliot
, Justine Boles
, et al.
·
Advances in Therapy
·
2
PDF
Pharmacokinetics of dolutegravir with and without darunavir/cobicistat in healthy volunteers
2019
·
Emilie R Elliot
, Maddalena Cerrone
, et al.
·
Journal of Antimicrobial Chemotherapy
·
2
PDF
Once-daily atazanavir/cobicistat and darunavir/cobicistat exposure over 72 h post-dose in plasma, urine and saliva: contribution to drug pharmacokinetic knowledge
2017
·
Emilie R. Elliot
, Alieu Amara
, et al.
·
Journal of Antimicrobial Chemotherapy
·
2
PDF
VOGUE: Noninferior Efficacy of Dolutegravir/Lamivudine Versus Bictegravir/Emtricitabine/Tenofovir Alafenamide in Adults With HIV-1 Naive to Treatment
2026
·
Jade Ghosn
, Federico Pulido
, et al.
·
Open Forum Infectious Diseases
·
1
PDF
1586. Phase 3/3b Experience with Long-Acting Cabotegravir and Rilpivirine: Efficacy and Safety Outcomes Through Week 96 by Race
2022
·
Parul Patel
, Emilie Elliot
, et al.
·
Open Forum Infectious Diseases
·
1
PDF
Current Progress in the Pharmacogenetics of Infectious Disease Therapy
2017
·
E. Elliot
, T. Mahungu
, et al.
·
Elsevier eBooks
·
1
Population pharmacokinetics (PK) of dolutegravir (DTG) alone and following treatment switch
2016
·
Laura Dickinson
, Margherita Bracchi
, et al.
·
1
The Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of Dolutegravir and Cobicistat in the Treatment of Hiv
2020
·
Elliot, Emilie
·
University of Liverpool
Pharmacokinetics of dolutegravir with and without darunavir/cobicistat in healthy volunteers (vol 74, pg 149, 2019)
2019
·
Emilie R Elliot
, Maddalena Cerrone
, et al.
Once-daily atazanavir/cobicistat and darunavir/cobicistat exposure over 72 h post-dose in plasma, urine and saliva: contribution to drug pharmacokinetic knowledge (vol 72, pg 2035, 2017)
2017
·
Emilie R Elliot
, Alieu Amara
, et al.
Show more works
View as search
Works count:
24
Citation count:
405
H-index:
10
I10-index:
10
Year
Topic
Type
